Eli Lilly and Company (NYSE: LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational, non-opioid treatments for migraine and cluster …
Trial achieved its primary endpoint of pathological Complete Response Rate Trial achieved its secondary endpoint in operability (R0 rate) NBTXR3 demonstrated significant superiority and clinical …
Preliminary data from the first clinical trial of the company’s intracranial ultrasound implant, SonoCloud®, show a good safety profile and promising trends in overall survival …
As the first personalized cell and gene therapies are approved from small clinical trials, researchers propose the creation of publicly accessible databases to pull together …
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of clinical data on ARC-520, the company’s prior generation investigational medicine for the treatment of chronic …
Pilots MEDEI’s SMART-TRIAL data management platform to better document the efficacy and safety of its brain network activation technology One of the world’s leading neuro …
Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to 13.8% of their body weight after 52 weeks in …
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that updated phase 1 safety and efficacy data for DS-8201, an investigational HER2-targeting antibody drug conjugate …
In February 20th and 22nd and March 15th, Aegle is launching a series of webinars with the objective of demonstrating how the final prototype of the AEGLE …
Janssen-Cilag International NV (“Janssen”) presented a new analysis from VOYAGE 1 assessing efficacy responses based on absolute Psoriasis Area and Severity Index score (PASI), as …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
